文献速递骨肿瘤创伤骨科

肢体骨肉瘤患者不确定肺结节的自然病史与进展可能性

What Is the Natural History and Likelihood of Progression of Indeterminate Pulmonary Nodules in Patients With Extremity Osteosarcoma?
PubMed 文献 · Clin Orthop Relat Res · 2026-10-09

该研究回顾性分析了202例肢体骨肉瘤患者,其中40例存在不确定肺结节(<10 mm)。随访显示58%的不确定结节进展,25%的患者发展为确诊肺转移,中位进展时间19个月。不确定肺结节患者2年总生存率55%,低于无结节患者的76%,但未发现结节特征与进展或生存相关。

要点

  • 肢体骨肉瘤不确定肺结节(<10 mm)进展率为58%,25%发展为确诊肺转移。
  • 不确定肺结节患者2年总生存率55%,低于无肺结节患者的76%。
  • 结节大小、数量、侧别、钙化等特征与进展或生存无显著关联。

核心结论

  • 不确定肺结节患者的总生存期较无肺结节患者差,中位总生存期为27个月(95%CI 19-36)。
  • 未发现任何单个结节特征(大小、数量、侧别、钙化)与疾病进展相关。
  • 建议对不确定肺结节患者进行严密监测,直至开展更大规模的前瞻性研究。

研究设计与样本

  • 根据基线高分辨率胸部CT(0.625 mm层厚)分为三组:不确定肺结节组(结节<10 mm,n=40)、无肺结节组(n=146)、转移组(结节≥10 mm,n=16)。
  • 由盲法放射科医师独立审阅不确定结节组的CT,按大小(≤5 mm vs 6-10 mm)、数量、分布、侧别和钙化进行特征描述。
  • 进展定义为结节大小增加≥1 mm或数量增加≥1个;确诊肺转移定义为基线不确定结节在随访中最大直径增长至>10 mm。
  • 采用Kaplan-Meier法分析生存,Cox比例风险回归评估结节特征与生存的关联。

主要发现

  • 不确定肺结节组中58%(23/40)出现结节进展,25%(10/40)发展为确诊肺转移,中位进展时间19个月(范围3-22)。
  • 多因素Cox回归显示,结节大小、数量、侧别或钙化均与进展或生存无显著关联。
  • 不确定肺结节患者2年总生存率为55%(95%CI 40%-71%),无转移患者为76%(95%CI 70%-83%),差异有统计学意义(p<0.001)。
  • 不确定肺结节患者中位总生存期为27个月(95%CI 19-36)。

临床怎么用

  • 对肢体骨肉瘤患者基线CT发现的不确定肺结节(<10 mm)应保持警惕,因其进展和转移风险较高。
  • 鉴于不确定肺结节与较差生存相关,建议对此类患者进行严密随访监测。
  • 目前尚无特定结节特征可预测进展,不能仅凭大小、数量、侧别或钙化决定干预策略。

局限性

  • 本研究为单中心回顾性研究,样本量有限(不确定肺结节组仅40例)。
  • 作者指出不能排除样本量增大后某些结节特征与进展的关联可能显现。
  • 研究证据等级为III级(预后研究)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Indeterminate pulmonary nodules are frequently identified on staging chest CT scans in patients with extremity osteosarcoma; however, their malignant potential and prognostic implications remain unclear. Understanding the natural history of indeterminate pulmonary nodules and the prognostic value of individual nodule characteristics is important to help guide surveillance and management decisions. QUESTIONS/PURPOSES: (1) What proportion of indeterminate pulmonary nodules progress to overt pulmonary metastasis, and what is the median time to progression? (2) Are specific radiographic characteristics-such as size, number, laterality, and calcification-associated with nodule progression or survival? (3) Do patients with indeterminate pulmonary nodules at diagnosis have inferior overall survival compared with patients without pulmonary nodules? METHODS: We retrospectively reviewed 202 pediatric and adult patients with extremity osteosarcoma treated at a single institution between January 2016 and December 2022, with follow-up until June 2024. At initial presentation, we created three distinct study groups based on baseline high-resolution chest CT findings (0.625-mm slice thickness): group 1, those with indeterminate pulmonary nodules (patients presenting with any number of pulmonary nodules measuring < 10 mm [n = 40]); group 2, those without pulmonary nodules (patients with no detectable lung nodules [n = 146]); and group 3, those with metastasis (patients with pulmonary nodule(s) measuring ≥ 10 mm [n = 16]). Of the 40 patients with indeterminate pulmonary nodules, 58% (23 of 40) were male and 43% (17 of 40) were female, with a median (range) age at presentation of 16 years (7 to 53) High-resolution CT chest images of the indeterminate pulmonary nodule group were independently reviewed by a blinded radiologist, characterizing nodules by size (≤ 5 mm versus 6 to 10 mm), number, distribution, laterality, and calcification. Longitudinal nodule behavior was classified as progressive, regressive, or static. Progression was defined as an increase in size ≥ 1 mm or in number by ≥ 1; while regression was defined as a decrease in size ≥ 1 mm or in number by ≥ 1, with remaining nodules stable. Confirmed pulmonary metastases were defined specifically as any initial baseline indeterminate pulmonary nodule that demonstrated growth to a maximum diameter of > 10 mm during the longitudinal follow-up period. Chest CT scans were done before surgery and at completion of therapy. Thereafter, chest CT scans were performed every 3 months for the first 3 years, every 6 months between years 3 and 5, and annually after the fifth year. Survival outcomes were analyzed using Kaplan-Meier methods, and the association of nodule characteristics with survival was assessed with Cox proportional hazards regression. RESULTS: Overall, 58% (23 of 40) of indeterminate pulmonary nodules progressed across the follow-up period, with 25% (10 of 40) of patients developing confirmed pulmonary metastasis; the median (range) time to nodule progression was 19 months (3 to 22). No individual nodule characteristic-including size, number, laterality, or calcification-was associated with progression or survival on multivariate Cox regression analysis. Patients with indeterminate pulmonary nodules had worse 2-year overall survival than patients without metastasis (55% [95% confidence interval (CI) 40% to 71%] versus 76% [95% CI 70% to 83%]; p < 0.001). The median overall survival for patients with indeterminate pulmonary nodules was 27 months (95% CI 19 to 36). CONCLUSION: Our study showed an association with indeterminate pulmonary nodules and survival and suggests that patients who present with indeterminate pulmonary nodules have worse overall survival than those who do not. No individual nodule characteristic was associated with disease progression in our cohort, but we cannot exclude the possibility that with more numbers, an association might be present. Our study suggests that vigilant surveillance is warranted for patients with indeterminate pulmonary nodules until prospective studies with more patients are conducted to better develop evidence-based management and surveillance protocols. LEVEL OF EVIDENCE: Level III, prognostic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Suthar S, Krishnan CK, Perumal A, et al. What Is the Natural History and Likelihood of Progression of Indeterminate Pulmonary Nodules in Patients With Extremity Osteosarcoma? Clin Orthop Relat Res. 2026. PMID: 42853974. doi:10.1097/CORR.0000000000004152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。